OIPE JC10
MAR 30 2005
PATENT & TRADEMARK OFFICE

Modified Form 1449/PTO		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	**Application Number**	10/677,631
	Filing Date	October 2, 2003
	First Named Inventor	David J. Lauffer
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-113 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
EB	A1	5,811,434	Sep. 22, 1998	Zelle, et al.			
EB	A2	6,043,255	Mar. 28, 2000	Lowe, et al.			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
EB	B1	WO	01/58891	Vertex Pharmaceuticals Incorporated	16 August 2001		
EB	B2	WO	00/32588	GPI NIL Holdings Incorporated	8 June 2000		
EB	B3	WO	00/10533	Southern Research Institute	2 March 2000		
EB	B4	WO	98/20893	Vertex Pharmaceuticals Incorporated.	22 May 1998		

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
EB	C1	Magyar, et al., "The Action of Trelibet, a New Antidepressive Agent on [3H]noradrenaline Release From Rabbit Pulmonary Artery", European J. of Pharmacology, Vol. 130, Pages 219-227, (1986).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	E Bernhardt	Date Considered	6/19/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.